In Vivo Experiments

Products from Molecular Innovations are not sterile or tested for endotoxin unless marked otherwise. Protein solutions should be sterile filtered before injection. All products are for research use only.

PAI-1 in Rats: 2 mg/kg/day, administered twice daily by intraperitoneal injection.
Recombinant Plasminogen Activator Inhibitor-1 Inhibits Intimal Hyperplasia
Jianbo Wu, Lin Peng, Grainne A. McMahon, Daniel A. Lawrence, and William P. Fay
Arterioscler Thromb Vasc Biol, Oct 2009; 29: 1565 – 1570.

tPA in Mice: 2 ul of 1 uM solution after MCAO, intracortically injected (unilateral injection) over 5 min.
Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact
Benoit D. Roussel, Richard Macrez, Amandine Jullienne, Véronique Agin, Eric Maubert, Luce Dauphinot, Marie-Claude Potier, Laurent Plawinski, Hervé Castel, Yannick Hommet, Josep Munuera, Joan Montaner, Manuel Yepes, Carine Ali, and Denis Vivien
Brain, Aug 2009; 132: 2219 – 2230.

Other references:
Huang Y, Border WA, Lawrence DA, Noble NA.
Am J Physiol Renal Physiol. 2009 Oct;297(4):F1045-54. Epub 2009 Jul 22.
Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis.

Wu J, Peng L, McMahon GA, Lawrence DA, Fay WP.
Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1565-70. Epub 2009 Jul 2.
Recombinant plasminogen activator inhibitor-1 inhibits intimal hyperplasia.

Huang Y, Border WA, Yu L, Zhang J, Lawrence DA, Noble NA.
J Am Soc Nephrol. 2008 Feb;19(2):329-38. Epub 2008 Jan 23.
A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy.

Cao C, Lawrence DA, Li Y, Von Arnim CA, Herz J, Su EJ, Makarova A, Hyman BT, Strickland DK, Zhang L.
EMBO J. 2006 May 3;25(9):1860-70. Epub 2006 Apr 6.
Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration.

Stefansson S, Yepes M, Gorlatova N, Day DE, Moore EG, Zabaleta A, McMahon GA, Lawrence DA.
J Biol Chem. 2004 Jul 16;279(29):29981-7. Epub 2004 May 6.
Mutants of plasminogen activator inhibitor-1 designed to inhibit neutrophil elastase and cathepsin G are more effective in vivo than their endogenous inhibitors.

Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA.
J Clin Invest. 2003 Aug;112(3):379-88.
A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.

McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, Ginsburg D, Brooks PC, Lawrence DA.
J Biol Chem. 2001 Sep 7;276(36):33964-8. Epub 2001 Jul 5.
Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis.

Did You Find This Article Helpful?

Be the first to let us know!

Yes - 0 visitors found this post helpful
No - 0 visitors found this post was not helpful